Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients with Retinal Detachment

Launched by MASSACHUSETTS EYE AND EAR INFIRMARY · Sep 9, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a medication called netarsudil, which is applied directly to the eye, to see if it can help prevent a condition called proliferative vitreoretinopathy after surgery for retinal detachment. Proliferative vitreoretinopathy is a serious complication that can occur after retinal detachment surgery, and the trial aims to understand how well netarsudil works and how safe it is for patients before and after their surgery.

To be eligible for this trial, participants need to be at least 18 years old and should be undergoing surgery for a specific type of retinal detachment within a week of noticing symptoms. Certain health conditions or previous eye surgeries might exclude someone from participating. If enrolled, participants will receive eye drops and will be monitored for safety and any signs that the treatment is working. This trial is not yet recruiting patients, but it is an important step in finding better ways to manage eye health after retinal surgeries.

Gender

ALL

Eligibility criteria

• The primary rhegmatogenous detachment cohort will have the following selection criteria:
• Inclusion criteria:
• • Patients \> 18 years old
• • Patients presenting for primary rhegmatogenous retinal detachment repair within 7 days of symptom onset
• • Patients undergoing vitrectomy or vitrectomy with scleral buckle
• Exclusion criteria:
• • Patient unable to give consent
• • Patient unable to follow-up
• • Prior history of retinal detachment incisional surgery in presenting eye
• • Prior history of open globe injury to presenting eye
• • Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery, actively on glaucoma medication
• • Prior history of corneal disease, or history of corneal edema
• • Patient already on topical netarsudil in presenting eye
• • Patient without natural lens or intraocular lens implant (I.e., aphakic patients)
• • Patients with intraocular pressure \<8mm Hg in operative eye
• • Active or chronic or recurrent uncontrolled ocular or systemic disease
• • Active or history of chronic or recurrent inflammatory eye disease
• • Diagnosis of proliferative diabetic retinopathy
• • Signs of ocular infection at presentation in either eye
• • Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively
• • Inability to use/ apply topical eye drops
• The proliferative vitreoretinopathy cohort will have the following selection criteria:
• Inclusion criteria:
• • Patients \> 18 years old
• • Patient presenting with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma
• • Patients undergoing vitrectomy or vitrectomy with scleral buckle
• Exclusion criteria:
• • Patient unable to give consent
• • Patient unable to follow-up
• • Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery
• • Patient already on topical netarsudil in presenting eye
• • Patients with intraocular pressure \<8mm Hg in operative eye
• • Active or chronic or recurrent uncontrolled ocular or systemic disease
• • Active or history of chronic or recurrent inflammatory eye disease
• • Diagnosis of severe nonproliferative or proliferative diabetic retinopathy or vasoproliferative disease in operative eye
• • Signs of ocular infection at presentation in either eye
• • Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively
• • Inability to use/ apply topical eye drops
• • No Light Perception vision in operative eye
• • Failure to achieve intraoperative reattachment
• • Patient with silicone oil instilled in operative eye at time of presentation